Those factors include, among other things, agency resources and the threat to the public health. FDA also may consult with its federal and state partners in making decisions about whether to initiate a federal enforcement action. A. The FDA has sent warning letters in the past to companies illegally selling CBD products that claimed to prevent, diagnose, treat, or cure serious diseases, such as cancer. Some of these products were in further violation of the FD&C Act because they were marketed as dietary supplements or because they involved the addition of CBD to food.
: The anxiolytic potential of CBD is a topic of major interest in cannabinoid research. The cannabis compound has already proven itself useful in an early placebo-controlled study in patients with treatment-resistant schizophrenia. The molecule has also been shown to help relieve symptoms of post-traumatic stress disorder in animal models.
Within the endocannabinoid system is a network of cannabinoid receptors in the brain and central nervous system.The two primary receptors identified are CB1 and CB2. Not everything is completely understood about how cannabinoids work. What we do know from research is that CBD and cannabinoids interact with proteins and cells in the brain.
Read More:-